IL6 and prostate carcinoma: Mcl-1 is classified as an antiapoptotic protein that is overexpressed in many types of IL-6-treated cancer cells, including prostate cancer, myeloma, gastric cancer, and cholangiocarcinoma cells, but not in control cells [34].